Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MGX
stocks logo

MGX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
7.94M
-17.41%
-0.585
-7.14%
10.00M
+142.31%
-0.620
-8.82%
--
--
-0.620
+14.81%
Estimates Revision
The market is revising Downward the revenue expectations for Metagenomi, Inc. (MGX) for FY2025, with the revenue forecasts being adjusted by -1.44% over the past three months. During the same period, the stock price has changed by -6.28%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.44%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.38%
In Past 3 Month
Stock Price
Go Down
down Image
-6.28%
In Past 3 Month
Wall Street analysts forecast MGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGX is 8.67 USD with a low forecast of 7.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast MGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGX is 8.67 USD with a low forecast of 7.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.790
sliders
Low
7.00
Averages
8.67
High
12.00
Current: 1.790
sliders
Low
7.00
Averages
8.67
High
12.00
Chardan
Geulah Livshits
Buy
downgrade
$11 -> $7
2025-11-12
Reason
Chardan
Geulah Livshits
Price Target
$11 -> $7
2025-11-12
downgrade
Buy
Reason
Chardan analyst Geulah Livshits lowered the firm's price target on Metagenomi to $7 from $11 and keeps a Buy rating on the shares after the company reported Q3 results, announced the appointment of Dr. Jian Irish to CEO, and shared updated preclinical data on lead in vivo insertion program MGX-001 in hemophilia A. The firm updated its model for Q3 financials and removed the majority of platform value from the model in light of prioritization.
Chardan
downgrade
$12 -> $11
2025-08-15
Reason
Chardan
Price Target
$12 -> $11
2025-08-15
downgrade
Reason
Chardan lowered the firm's price target on Metagenomi to $11 from $12. The firm updated its model for Q2 financials and takes a slightly more conservative stance on programs/platform beyond hem A and the Ionis collaboration in light of the company's increasing focus on pipeline execution and advancing gene editing platform competition. The firm noted its Q2 adjustments shift its price target lower.
Wells Fargo
Yanan Zhu
Overweight
downgrade
$20 -> $16
2025-05-14
Reason
Wells Fargo
Yanan Zhu
Price Target
$20 -> $16
2025-05-14
downgrade
Overweight
Reason
Wells Fargo analyst Yanan Zhu lowered the firm's price target on Metagenomi to $16 from $20 on updated model assumption, while keeping an Overweight rating on the shares. The firm notes updated NHP data from the Hem A program demonstrate stable FVIII levels out to 19 months, boding well for a differentiated product profile and also providing preclinical validation for the secreted protein platform.
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Maintains
$14 → $7
2025-04-03
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$14 → $7
2025-04-03
Maintains
Strong Buy
Reason
Wells Fargo
Yanan Zhu
Buy
Maintains
$25 → $20
2025-03-18
Reason
Wells Fargo
Yanan Zhu
Price Target
$25 → $20
2025-03-18
Maintains
Buy
Reason
Wells Fargo analyst Yanan Zhu lowered the firm's price target on Metagenomi (MGX) to $20 from $25 and keeps an Overweight rating on the shares. With key initiatives progressing on track, the firm looks forward to the final NHP FVIII durability analysis in the first half of 2025 as well as updates on Ionis (IONS) collaboration programs and preclinical PoC for a secreted protein deficiency target this year.
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Maintains
$7 → $14
2024-12-10
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$7 → $14
2024-12-10
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Metagenomi Inc (MGX.O) is -0.71, compared to its 5-year average forward P/E of -1.32. For a more detailed relative valuation and DCF analysis to assess Metagenomi Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.32
Current PE
-0.71
Overvalued PE
-0.39
Undervalued PE
-2.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.26
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.29
Undervalued EV/EBITDA
-1.78

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.93
Current PS
0.00
Overvalued PS
6.28
Undervalued PS
1.59
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 323.12% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MGX News & Events

Events Timeline

(ET)
2025-11-11
16:10:40
Metagenomi CEO Brian Thomas to Step Down, Jian Irish to Take Over
select
2025-11-11
16:09:12
Metagenomi cuts its workforce by 25%
select
2025-11-11
16:07:22
Metagenomi Announces New Dose Range Findings for MGX-001 in Hemophilia A Program
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-03WSJ
Amazon's Custom Chips Present a New Challenge for Nvidia

  • Amazon's New AI Chip: Amazon Web Services has launched its Trainium3 custom AI chip, which is claimed to be four times faster than its previous AI chips.

  • Cost Efficiency: The Trainium3 chip can potentially reduce the costs of training and operating AI models by up to 50% compared to systems using equivalent GPUs.

[object Object]
Preview
2.0
12-01NASDAQ.COM
Biotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet

  • BioAtla Inc. Gains: BioAtla's shares surged 13.94% in after-hours trading, attributed to investor reactions to recent financing agreements, despite no new company-specific news.

  • Metagenomi Inc. and PAVmed Inc. Movements: Metagenomi's stock rose 5.71% with no new updates, while PAVmed advanced 5.72% after reporting a significant net loss and a sharp decline in revenue.

  • Precision BioSciences' Positive Outlook: Precision BioSciences gained 2.94% after announcing it will present Phase 1 trial data at an upcoming conference, boosting investor optimism.

  • Entero Therapeutics Rebranding: Entero Therapeutics' shares increased 3.68% following its announcement of a rebranding to GridAI Technologies Corp., effective December 1, 2025, along with a new ticker symbol.

[object Object]
Preview
9.5
11-12NASDAQ.COM
Metagenomi (MGX) Posts Q3 Loss, Falls Short of Revenue Projections

  • Quarterly Performance: Metagenomi reported a quarterly loss of $0.55 per share, slightly better than the expected loss of $0.60, but worse than a loss of $0.45 per share a year ago. The company also posted revenues of $8.66 million, missing estimates by 6.44%.

  • Stock Performance: Metagenomi shares have declined by approximately 40.4% since the start of the year, contrasting with a 16.2% gain in the S&P 500. The stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.

  • Earnings Outlook: The consensus EPS estimate for the upcoming quarter is -$0.50 on revenues of $9.26 million, while the fiscal year estimate is -$2.39 on $30.44 million in revenues. The mixed trend in earnings estimate revisions could influence future stock performance.

  • Industry Context: The Medical - Drugs industry, to which Metagenomi belongs, is currently ranked in the top 33% of Zacks industries, suggesting a favorable environment for stocks in this sector. Another company in the same industry, Nutriband Inc., is expected to report a significant loss in its upcoming results.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Metagenomi Inc (MGX) stock price today?

The current price of MGX is 1.79 USD — it has increased 1.13 % in the last trading day.

arrow icon

What is Metagenomi Inc (MGX)'s business?

Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.

arrow icon

What is the price predicton of MGX Stock?

Wall Street analysts forecast MGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGX is 8.67 USD with a low forecast of 7.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Metagenomi Inc (MGX)'s revenue for the last quarter?

Metagenomi Inc revenue for the last quarter amounts to 8.66M USD, decreased -24.80 % YoY.

arrow icon

What is Metagenomi Inc (MGX)'s earnings per share (EPS) for the last quarter?

Metagenomi Inc. EPS for the last quarter amounts to -0.55 USD, increased 7.84 % YoY.

arrow icon

What changes have occurred in the market's expectations for Metagenomi Inc (MGX)'s fundamentals?

The market is revising Downward the revenue expectations for Metagenomi, Inc. (MGX) for FY2025, with the revenue forecasts being adjusted by -1.44% over the past three months. During the same period, the stock price has changed by -6.28%.
arrow icon

How many employees does Metagenomi Inc (MGX). have?

Metagenomi Inc (MGX) has 202 emplpoyees as of December 05 2025.

arrow icon

What is Metagenomi Inc (MGX) market cap?

Today MGX has the market capitalization of 67.02M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free